Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors

Press Release
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
July 29, 2022 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Jean-Francois Labbé, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022. Michele Garufi, who has filled the role ad interim since June 1, 2022, will remain as a Board member. “I am taking up this role at a very exciting time for the company, with Andreas Segerros having joined us recently as Chief Executive Officer and with our first pivotal Phase 3 data on NCX 470 in glaucoma due in November of this year. I look forward to working with Andreas and the Executive Team as we prepare Nicox to continue its development on the back of the NCX 470 clinical data.” said Jean-Francois Labbé, Chairman of Nicox. “On behalf of the Company and the Board of Directors, I would like to express my appreciation for the leadership, dedication and motivation that Michele Garufi brought, both as Chairman and as Chief Executive Officer, since the inception of the company. We are pleased we will continue to benefit from his experience through his position on the Nicox Board.” “The appointment of Jean-Francois Labbé as Chairman of the Board completes the Board and management reorganization which began when I joined the company two months ago. The company is well-positioned to move forward with a strong and experienced executive management and a supportive and effective Board, in a good governance structure.” said Andreas Segerros, Chief Executive Officer of Nicox. Jean-Francois Labbé Jean-François Labbé has served as a member of Nicox’ Board of Directors since June 2010 and has been the Chairman of the Audit Committee of Nicox since July 2013. M. Labbé is the Founder and Chief Executive Officer of SpePharm Holding BV, a pan-European specialty pharma company. Prior to founding SpePharm, M. Labbé served as Chief Executive Officer of OTL Pharma SA from 2001 to 2004 and as Chief Operating Officer of ProStrakan UK from 2004 to 2005. He began his career at Roussel Uclaf in 1974, then Hoechst Roussel and HMR, where he served in various positions in Europe, the United States and was a member of the HMR’s Executive Committee before its merger with Aventis in 1999. M. Labbé received an MBA from the Ecole des Hautes Études Commerciales (HEC), Paris, France.
About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co         Dylan Van Haaften        Paris, France Edison Investment Research        Pooya Hemami        London, UK H.C. Wainwright & Co        Yi Chen        New York, U.S. Kepler Cheuvreux        Arsene Guekam        Paris, France
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Nicox Gavin Spencer Executive Vice President, Chief Business Officer & Head of Corporate Development T [phone] [e-mail]	Investors & Media United States & Europe LifeSci Advisors, LLC Sandya von der Weid T [phone] [e-mail]
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox’s website (www.nicox.com)
Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T [phone] F [phone]

 

Attachment

• EN_ AnnouncementChairmanJFL_ PR_20220729_F